Kurma Partners — Activity | F4

Team Portfolio Raise Read Contact

F4/Kurma Partners/Activity

Kurma Partners Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

New Fund

Kurma Partners closed Biofund IV at €215M, bringing total AUM across all franchises to €1 billion.

Kurma Biofund IV — €215M Final Close

kurmapartners.comAPR 2026

medcitynews.com

en.newsroom.eurazeo.com

APR 2026

Exit

Portfolio company PathoQuest (NGS-based biosafety) announced acquisition by Charles River Laboratories.

PathoQuest

PathoQuest Kurma Partners

kurmapartners.comJAN 2026

JAN 2026

Investment

Participated in Alveus Therapeutics' $160M Series A for next-generation obesity and metabolic disease therapies.

Alveus Therapeutics

Alveus Therapeutics Kurma Partners

globenewswire.comJAN 2026

JAN 2026

Investment

Co-led Adcytherix's €105M Series A — the largest ADC-focused Series A in Europe in 2025.

Adcytherix

Adcytherix Kurma Partners

adcytherix.comOCT 2025

eu-startups.com

OCT 2025

Exit

Founding shareholder ImCheck Therapeutics acquired by Ipsen for up to €1 billion (€350M upfront).

ImCheck Therapeutics

ImCheck Therapeutics Kurma Partners

kurmapartners.comOCT 2025

OCT 2025

Exit

Portfolio company Stilla Technologies (digital PCR) acquired by Bio-Rad Laboratories for $225M plus up to $50M in milestones.

Stilla Technologies

Stilla TechnologiesKurma Partners

kurmapartners.comFEB 2025

FEB 2025

New Fund

Achieved first close of Biofund IV at €140M toward a €250M target, with cornerstone investors CSL, EIF, and Bpifrance.

Kurma Biofund IV — €140M First Close

kurmapartners.comOCT 2024

globenewswire.com

OCT 2024

Team Change

Amanda Gett-Chaperot joined Kurma Partners as Partner to the Biofund venture team, bringing venture, industry, and research expertise.

Amanda Gett joined as Partner

kurmapartners.comOCT 2023

OCT 2023